Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Astatine-211 Radiopharmaceuticals; Status, Trends, and the Future Publisher Pubmed



Rabiei M1 ; Asadi M2 ; Yousefnia H3
Authors

Source: Current Radiopharmaceuticals Published:2024


Abstract

The low range of alpha particles provides an opportunity to better target cancer cells theoretically leading to the introduction of interesting alpha emitter radiopharmaceuticals including225Ac,212Pb, etc. The combination of high energy and short range of alpha emitters differentiates targeted radiotherapy from other methods and reduces unwanted cytotoxicity of the cells around the tumoral tissue. Among interesting alpha emitters candidates for targeted therapy,211At, one of the radioisotopes with the best optimal decay properties, shows great promise for targeted radiotherapy in some animal prostate cancer xenograft studies and bone micro tumors with significant effects compared to other beta and alpha emitters and also demonstrates interesting properties for clinical applications. However, production and application of this alpha emitter in the development of actinium-based radiopharmaceuticals is hampered by many obstacles. This mini-review demonstrates211At production methods, chemical separation, radiolabeling procedures,211At-radiopharmaceuticals and their clinical trials, transport, logistics, and costs and future trends in the field for ultimate clinical applications. This review showed that there are limited clinical trials on211Ac-based radiopharmaceuticals, which is due to the low accessibility of this radioisotope and other limitations. However, the development programs of major industries indicate the development of211Ac-based radiopharmaceuticals in the future. © 2024 Bentham Science Publishers.
Related Docs
View other Related Docs
1. Recent Achievements About Targeted Alpha Therapy-Based Targeting Vectors and Chelating Agents, Anti-Cancer Agents in Medicinal Chemistry (2022)
2. Targeted Radioligand Therapy: Physics and Biology, Internal Dosimetry and Other Practical Aspects During 177Lu/225Ac Treatment in Neuroendocrine Tumors and Metastatic Prostate Cancer, Theranostics (2025)
3. Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain, Journal of Clinical Medicine (2020)
Experts (# of related papers)
View all Related Experts
Davood Beiki (5)
Ghazaleh Geraily (4)
Other Related Docs
4. Dosimetric Evaluation of 153Sm-Edtmp, 177Lu-Edtmp and 166Ho-Edtmp for Systemic Radiation Therapy: Influence of Type and Energy of Radiation and Half-Life of Radionuclides, Radiation Physics and Chemistry (2015)
5. Application of Nano-Radiosensitizers in Combination Cancer Therapy, Bioengineering and Translational Medicine (2023)
6. 177Lu-Labeled Cyclic Rgd Peptide As an Imaging and Targeted Radionuclide Therapeutic Agent in Non-Small Cell Lung Cancer: Biological Evaluation and Preclinical Study, Bioorganic Chemistry (2020)
7. Metformin As a Radiation Modifier; Implications to Normal Tissue Protection and Tumor Sensitization, Current Clinical Pharmacology (2019)
8. Optimal Indications of Radioimmunotherapy in Nuclear Medicine: A Mini-Review, Current Radiopharmaceuticals (2024)
9. Evaluation of 153Sm/177Lu-Edtmp Mixture in Wild-Type Rodents As a Novel Combined Palliative Treatment of Bone Pain Agent, Journal of Radioanalytical and Nuclear Chemistry (2015)
10. Comparison of Dsb Effects of the Beta Particles of Iodine-131 and 6 Mv X-Ray at a Dose of 2 Gy in the Presence of 2-Methoxyestradiol, Iudr, and Tpt in Glioblastoma Spheroids, Radiation Physics and Chemistry (2017)
11. Feasibility of 18-Mv Grid Therapy From Radiation Protection Aspects: Unwanted Dose and Fatal Cancer Risk Caused by Photoneutrons and Scattered Photons, Computer Methods and Programs in Biomedicine (2022)
12. The Effect of Bismuth Nanoparticles in Kilovoltage and Megavoltage Radiation Therapy Using Magnetic Resonance Imaging Polymer Gel Dosimetry, Radiation Physics and Chemistry (2020)
13. Bismuth Oxide Nanoparticles As Agents of Radiation Dose Enhancement in Intraoperative Radiotherapy, Medical Physics (2021)
14. Head and Neck and Skin (Hns) Gec-Estro and Braphyqs Working Groups Joint Critical Review of the Use of Rhenium-188 in Dermato-Oncology, Clinical and Translational Radiation Oncology (2025)
15. An in Silico Study on the Effect of Host Tissue at Brachytherapy Dose Enhancement by Gold Nanoparticles, Brachytherapy (2021)
16. Development and Evaluation of [64Cu]Cu-Dotatate for Clinical Applications, Iranian Journal of Nuclear Medicine (2023)
17. Gamma-Ray Involved in Cancer Therapy and Imaging, Electromagnetic Waves-Based Cancer Diagnosis and Therapy: Principles and Applications of Nanomaterials (2023)
18. Radiosynthesis, Biological Evaluation, and Preclinical Study of a 68Ga-Labeled Cyclic Rgd Peptide As an Early Diagnostic Agent for Overexpressed Α V Β 3 Integrin Receptors in Non-Small-Cell Lung Cancer, Contrast Media and Molecular Imaging (2020)
19. Dosimetry and Radioenhancement Comparison of Gold Nanoparticles in Kilovoltage and Megavoltage Radiotherapy Using Magat Polymer Gel Dosimeter, Journal of Biomedical Physics and Engineering (2019)
20. Determination of Human Absorbed Dose From [153Sm]-Samarium Maltolate Based on Distribution Data in Rats, International Journal of Radiation Research (2015)